Key Takeaways
- • Blackstone-managed funds will provide up to $1.5 billion in development funding through 2028 for berobenatide, Pfizer's investigational monthly GLP-1 receptor agonist for chronic weight management and obesity-related conditions.
- • Blackstone's return is milestone-based, tied to U.S. regulatory approval of monthly injectable berobenatide monotherapy and to specified sales targets, with milestone payments distributed over multiple years.
- • The structure involves no ownership interest or commercial rights for Blackstone; Pfizer retains full operational control and decision-making authority over the drug.
- • Pfizer plans more than 20 clinical trials in 2026 involving obesity and related conditions, including 10 ongoing and planned Phase 3 trials for berobenatide.
- • Blackstone Life Sciences, which manages approximately $18 billion in assets, expands an existing relationship with Pfizer; BXPE, Blackstone's perpetual private equity strategy, will participate alongside Blackstone Life Sciences funds.
Summary
Pfizer and Blackstone Life Sciences have entered into a strategic funding agreement under which funds managed by Blackstone will provide up to $1.5 billion through 2028 to support the clinical development of berobenatide, according to the company's announcement. Berobenatide is being developed as a potential first-in-class monthly injectable GLP-1 receptor agonist peptide, and Pfizer is evaluating it for chronic weight management and obesity-related conditions, including knee osteoarthritis and obstructive sleep apnea.
Under the arrangement, Blackstone-managed funds will cover up to $1.5 billion in development expenses associated with the drug. In return, Blackstone will be eligible for milestone-based payments tied to U.S. regulatory approval of monthly injectable berobenatide monotherapy for chronic weight management and to the achievement of certain sales targets. Any milestone payments would be distributed over multiple years. Funds managed by BXPE, Blackstone's perpetual private equity strategy, will participate alongside funds managed by Blackstone Life Sciences. The structure allows Pfizer to obtain external funding for a major development program without selling ownership or commercial rights, and Pfizer will retain full operational control over berobenatide, including its clinical development strategy.
Pfizer plans to advance more than 20 clinical trials involving obesity and associated conditions during 2026, including 10 ongoing and planned Phase 3 trials for berobenatide. The company is also studying berobenatide in combination with other investigational therapies, including nutrient-stimulated hormone peptides such as amylin analogs. Berobenatide remains investigational, and its safety, effectiveness and potential approval have not yet been established by regulators. Pfizer has not announced a regulatory approval or commercial launch date.
Blackstone Life Sciences, which provides capital and operational expertise to pharmaceutical, biotechnology and medical technology businesses and manages approximately $18 billion in assets, described the drug as the anchor of Pfizer's cardiometabolic pipeline. Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences, said the collaboration reflects the firm's leadership in providing capital solutions at scale. Pfizer CFO Cecile Guegan said the agreement pairs internal research investment with targeted capital from partners while maintaining financial flexibility across the broader pipeline. The agreement does not guarantee regulatory approval or commercial success, and returns depend on future regulatory and commercial outcomes.
Under the arrangement, Blackstone-managed funds will cover up to $1.5 billion in development expenses associated with the drug. In return, Blackstone will be eligible for milestone-based payments tied to U.S. regulatory approval of monthly injectable berobenatide monotherapy for chronic weight management and to the achievement of certain sales targets. Any milestone payments would be distributed over multiple years. Funds managed by BXPE, Blackstone's perpetual private equity strategy, will participate alongside funds managed by Blackstone Life Sciences. The structure allows Pfizer to obtain external funding for a major development program without selling ownership or commercial rights, and Pfizer will retain full operational control over berobenatide, including its clinical development strategy.
Pfizer plans to advance more than 20 clinical trials involving obesity and associated conditions during 2026, including 10 ongoing and planned Phase 3 trials for berobenatide. The company is also studying berobenatide in combination with other investigational therapies, including nutrient-stimulated hormone peptides such as amylin analogs. Berobenatide remains investigational, and its safety, effectiveness and potential approval have not yet been established by regulators. Pfizer has not announced a regulatory approval or commercial launch date.
Blackstone Life Sciences, which provides capital and operational expertise to pharmaceutical, biotechnology and medical technology businesses and manages approximately $18 billion in assets, described the drug as the anchor of Pfizer's cardiometabolic pipeline. Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences, said the collaboration reflects the firm's leadership in providing capital solutions at scale. Pfizer CFO Cecile Guegan said the agreement pairs internal research investment with targeted capital from partners while maintaining financial flexibility across the broader pipeline. The agreement does not guarantee regulatory approval or commercial success, and returns depend on future regulatory and commercial outcomes.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.